HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer.

HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer.

Cisplatin is a widely used chemotherapy agent in the treatment of non-small cell lung cancer (NSCLC). However, its clinical efficacy is limited by the development of drug resistance in patients with NSCLC. Recently, we demonstrated that HMGB1-BoxA gene therapy (BoxA) is an ideal cancer treatment tha...

Full description

Saved in:
Bibliographic Details
Main Authors: Nattapong Puthdee, Van-Hieu Mai, Sirapat Settayanon, Pithi Chanvorachote, Chatchawit Aporntewan, Apiwat Mutirangura, Chanida Vinayanuwattikun
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0327144
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items